Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days after the event.
Design Therapeutics (NASDAQ: DSGN), una società biotecnologica in fase clinica specializzata nello sviluppo di terapie per gravi malattie genetiche degenerative, ha annunciato la sua partecipazione alla 2025 Jefferies Global Healthcare Conference. Il management dell'azienda terrà una presentazione il mercoledì 4 giugno 2025, alle 14:35 ET a New York. Gli interessati potranno seguire la presentazione in diretta streaming tramite il sito web dell'azienda o il link fornito; la registrazione sarà disponibile per almeno 30 giorni dopo l'evento.
Design Therapeutics (NASDAQ: DSGN), una empresa biotecnológica en fase clínica enfocada en desarrollar tratamientos para graves enfermedades genéticas degenerativas, ha anunciado su participación en la próxima Conferencia Global de Salud Jefferies 2025. La dirección de la empresa realizará una presentación el miércoles 4 de junio de 2025 a las 2:35 p.m. ET en Nueva York. Los interesados podrán acceder a una transmisión en vivo de la presentación a través del sitio web de la empresa o mediante el enlace proporcionado, con la grabación disponible al menos 30 días después del evento.
Design Therapeutics (NASDAQ: DSGN)는 심각한 퇴행성 유전 질환 치료제 개발에 주력하는 임상 단계 바이오테크 기업으로, 다가오는 2025 Jefferies 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사 경영진은 2025년 6월 4일 수요일 오후 2시 35분(동부시간) 뉴욕에서 발표를 진행할 예정입니다. 관심 있는 분들은 회사 웹사이트 또는 제공된 링크를 통해 발표를 실시간 웹캐스트로 시청할 수 있으며, 녹화 영상은 행사 후 최소 30일간 제공됩니다.
Design Therapeutics (NASDAQ : DSGN), une société biotechnologique en phase clinique spécialisée dans le développement de traitements pour les maladies génétiques dégénératives graves, a annoncé sa participation à la Jefferies Global Healthcare Conference 2025. La direction de l'entreprise présentera le mercredi 4 juin 2025 à 14h35 ET à New York. Les personnes intéressées pourront suivre la présentation en direct via le site web de la société ou le lien fourni, l'enregistrement restant disponible pendant au moins 30 jours après l'événement.
Design Therapeutics (NASDAQ: DSGN), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für schwere degenerative genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden 2025 Jefferies Global Healthcare Conference angekündigt. Die Geschäftsleitung des Unternehmens wird am Mittwoch, den 4. Juni 2025, um 14:35 Uhr ET in New York eine Präsentation halten. Interessierte können die Präsentation live über die Website des Unternehmens oder den bereitgestellten Link verfolgen; die Aufzeichnung ist mindestens 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York.
A live webcast of the presentation will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) presenting at the 2025 Jefferies Healthcare Conference?
How can I watch Design Therapeutics' (DSGN) presentation at the Jefferies Conference?
How long will Design Therapeutics' (DSGN) Jefferies Conference presentation be available to view?
What type of company is Design Therapeutics (DSGN)?
